EirGen Pharma
- Company typePrivate
- Founded2005
- HeadquartersWaterford, Ireland
- Headcount101–250
- GTM typeB2B
- OfferingServices
EirGen Pharma firmographics
Firmographics- Name
- EirGen Pharma
- Legal name
- Eirgen Pharma Limited
- Website
- https://eirgen.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
EirGen Pharma industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where EirGen Pharma is headquartered
LocationHeadquarters
- HQ city
- Waterford
- HQ country
- Ireland
- HQ region
- Europe
Offices2 records
Markets served
EirGen Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development & Manufacturing (CDMO): Eirgen provides end-to-end pharmaceutical development and manufacturing services including pre-formulation, formulation development, process optimization, tech transfer, scale-up, GMP clinical and commercial manufacturing, and packaging. Revenue is generated through project fees, milestone payments, and ongoing manufacturing supply contracts with pharmaceutical partners.
- Product Portfolio & Licensing: Eirgen holds production rights for a portfolio of OSD products and offers in-licensing and out-licensing opportunities for market expansion, generating revenue through product royalties and licensing agreements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based CDMO services with customized pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
EirGen Pharma product offering
Product offeringCore offering
EirGen Pharma is a specialist oral solid dose (OSD) Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical development, manufacturing, and packaging services. Its core offerings include High-Potency and Cytotoxic OSD manufacturing, Softgel Development and Manufacturing, Oral Solid Dose Development, Contract Packaging and Serialization, and Companion Animal Health services. The company operates purpose-built high-containment facilities in Waterford, Ireland, approved by FDA, EMA, HPRA, PMDA, and MRHA, supplying medicines across more than 60 countries.
Product overview
EirGen Pharma is a specialist oral solid dose (OSD) Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical development, manufacturing, and packaging services. The company's core offerings include High-Potency & Cytotoxic OSD manufacturing, Softgel Development & Manufacturing, Oral Solid Dose Development, Contract Packaging & Serialization, and Companion Animal Health services. These are complemented by Pharmaceutical Development Services, Tech-Transfer & Scale-Up, Analytical Services, and Regulatory & Compliance support. EirGen also offers Product Portfolio management with in-licensing and out-licensing opportunities. The company operates from Waterford, Ireland, with facilities approved by FDA, EMA, HPRA, PMDA, and MRHA.
Differentiator
Problem solved
Functional benefit
Products and services
- High-Potency & Cytotoxic OSD Manufacturing Specialized HPAPI and cytotoxic oral solid dose manufacturing in purpose-built high-containment facilities for pharmaceutical companies requiring safe, compliant manufacturing and reliable commercial supply.
- Softgel Development & Manufacturing Specialist softgel formulation and manufacturing to maximize bioavailability, improve stability, and deliver patient-centric dosage solutions for complex molecules. Ireland's only pharmaceutical softgel manufacturer.
- Oral Solid Dose Development End-to-end OSD development and scale-up for tablets, capsules, and complex formulations from early-stage design through global commercial supply for pharmaceutical partners.
- Contract Packaging & Serialization Integrated clinical and commercial packaging, serialization (2D matrix, DSCSA-aligned), aggregation, artwork management, and traceability to deliver compliant, market-ready drug products.
- Companion Animal Health Manufacturing Specialized development and manufacturing of oral solid dose products for animal health, supporting the veterinary pharmaceutical market with species-specific formulations including palatable and modified-release formats.
- Pharmaceutical Development Services Pre-formulation, formulation development, and process optimization for oral solid doses including tablets and capsules, supporting pharmaceutical clients from early development onward.
- Tech-Transfer & Scale-Up Services Rapid technology transfer and process scaling from clinical development to commercial manufacturing for pharmaceutical partners.
- Analytical Services Method validation, stability programs, and quality control testing for pharmaceutical products, with over 50 scientists in on-site R&D and analytical laboratories.
- Regulatory & Compliance Services Comprehensive regulatory support across FDA, EMA, HPRA, PMDA, and MRHA pathways, accelerating development and reducing onboarding risk for pharmaceutical partners.
- Product Portfolio (In-Licensing & Out-Licensing) Broad portfolio of OSD products with production rights, offering in-licensing and out-licensing opportunities to marketing authorization holders to expand market access across regions.
Quantifiable outcome
- 8.82 out of 10 overall customer satisfaction score
- +4 more outcomes
Companies that use EirGen Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
EirGen Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
EirGen Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered significant and core.
- Nicoya TherapeuticssignificantEirGen Pharma (subsidiary of OPKO Health) amended its agreement with Nicoya Therapeutics, granting an expanded license to commercialize RAYALDEE® in Greater China. The agreement includes a revised tiered royalty and transfer price schedule and expanded field of use. RAYALDEE is already approved in Macau with regulatory approvals in China and related territories expected in 2027. OPKO received a 15% equity stake in Nicoya through Series A-2 Preferred Shares.
- OPKO HealthcoreEirgen Pharma became part of the OPKO Health family in 2015. Under OPKO ownership, Eirgen has expanded R&D capabilities and GMP-compliant manufacturing facilities. The parent company's infrastructure has supported Eirgen's growth into a global CDMO leader.
Scale indicators11 records
Recent moves7 records
Expansion highlights5 records
EirGen Pharma competitors and assessment
Company assessmentBroad incumbents
- Lonza: One of the world's largest CDMOs with broad capabilities spanning small molecules, biologics, and oral dosage forms including high-potency. A broader incumbent offering overlapping capabilities to Eirgen's pharmaceutical clients.
- Patheon (Thermo Fisher Scientific): Global pharmaceutical services division of Thermo Fisher offering end-to-end drug development and manufacturing including OSD. Broader incumbent with significant scale competing across all CDMO services.
Direct peers
- Hovione: Specialist CDMO with strong capabilities in HPAPI and high-potency drug product manufacturing, including OSD. Competes directly with Eirgen in complex, high-containment pharmaceutical manufacturing.
- Recipharm: European CDMO with significant oral solid dose manufacturing capabilities, including high-potency products. Direct competitor for pharmaceutical OSD contract manufacturing projects.
- Catalent: Global CDMO offering softgel, oral solid dose, and high-potency manufacturing services across multiple sites. Direct competitor to Eirgen in OSD and softgel CDMO services for pharmaceutical clients.
- Siegfried Holding: Swiss-headquartered CDMO with significant oral solid dose manufacturing capacity for both small molecules and high-potency compounds. Comparable European-based CDMO with similar OSD focus.
- Aenova Group: European CDMO with strong oral solid dose manufacturing capabilities for the pharmaceutical industry. Direct competitor in the European OSD contract manufacturing market.
- Quotient Sciences: CDMO focused on oral dosage form development and clinical manufacturing with integrated drug development services. Comparable in offering pharmaceutical development and small-batch OSD manufacturing.
Regional players
- Almac Group: Northern Ireland-based contract development and manufacturing organization offering OSD, API, and analytical services. Geographic and service overlap with Eirgen within the UK and Irish pharmaceutical market.
Emerging players
- Alcami Corporation: US-headquartered CDMO offering oral solid dose development, manufacturing, and analytical services. Overlapping service portfolio with Eirgen, particularly in small-batch and niche pharmaceutical manufacturing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EirGen Pharma social profiles
Digital presenceEirGen Pharma compliance and trust
Trust signalCompliance6 records
EirGen Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
EirGen Pharma leadership team
Management profileNumber of profiles
Profiles8 records
EirGen Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EirGen Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EirGen Pharma
What does EirGen Pharma do?
EirGen Pharma is a specialist oral solid dose (OSD) Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical development, manufacturing, and packaging services. Its core offerings include High-Potency and Cytotoxic OSD manufacturing, Softgel Development and Manufacturing, Oral Solid Dose Development, Contract Packaging and Serialization, and Companion Animal Health services. The company operates purpose-built high-containment facilities in Waterford, Ireland, approved by FDA, EMA, HPRA, PMDA, and MRHA, supplying medicines across more than 60 countries.
Is EirGen Pharma a public or private company?
EirGen Pharma is a private company. It is classified as corporate owned and is currently operating.
When was EirGen Pharma founded?
EirGen Pharma was founded in 2005. It employs 101 to 250 people.
Where is EirGen Pharma based?
EirGen Pharma is headquartered in Waterford, Ireland, in the Europe region.
How does EirGen Pharma make money?
Two revenue lines are on record. Contract Development & Manufacturing (CDMO) is the primary driver. The others are product Portfolio & Licensing.
Who are EirGen Pharma's main competitors?
Broad incumbents on record are Lonza and Patheon (Thermo Fisher Scientific). Direct peers are Hovione, Recipharm, Catalent, Siegfried Holding, Aenova Group and Quotient Sciences. Almac Group is listed as a regional player. Alcami Corporation is listed as an emerging player.
Does EirGen Pharma have an API?
No public API is recorded for EirGen Pharma.
What industry is EirGen Pharma in?
EirGen Pharma's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAJ, Packaging, Labeling & Serialization (Clinical/Commercial) CDMO. Its NAICS code is 325412 and its SIC code is 2834.